Prostate Cancer

New Indication: Talazoparib and Enzalutamide in Metastatic CRPC

2023-06-24

  • Study

    Double-blind, placebo-controlled phase 3 trial (TALAPRO-2)
    Previously untreated, CRPC
    Enzalutamide + talazoparib (n=402) vs. Enzalutamide+ PBO (n=403


  • Efficacy

    ITT:
    mrPFS: NR [27.5 mos-NR] vs 21.9 mos, HR:0.63, p<0.0001

    HRRm subgroup
    mrPFS: 27.9 vs 16.4 mos, HR:0.45, p=0.0003

    HRR non-deficient or unknown subgroup
    mrPFS: NR [27.5 vs NR] vs 22.5 mos, HR:0.70, p=0.003


  • Safety

    Grade≥3 AEs: Anemia (15.1% vs 3.3%), hypertension (3.5% vs 3.3%), venous emboli and thrombosis (6.8% vs 2.0%)


    • Lancet Oncol 2023 Jul 22;402(10398):291-303

    Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomized, placebo-controlled, phase 3 trial.

    http://doi.org/10.1016/S0140-6736(23)01055-3

    Reviewed by Elvin Chalabiyev, MD on Jun 24, 2023